Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.verified

ALNY

Price:

$147.76

Market Cap:

$18.69B

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1)...[Read more]

Industry

Biotechnology

IPO Date

2004-06-01

Stock Exchange

NASDAQ

Ticker

ALNY

The PE Ratio as of May 2024 (TTM) for Alnylam Pharmaceuticals, Inc. (ALNY) is -55.97

According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -55.97. This represents a change of 121.99% compared to the average of -25.21 of the last 4 quarters.

Alnylam Pharmaceuticals, Inc. (ALNY) Historical PE Ratio (quarterly & annually)

How has ALNY PE Ratio performed in the past?

The mean historical PE Ratio of Alnylam Pharmaceuticals, Inc. over the last ten years is -22.32. The current -55.97 PE Ratio has changed 24.98% with respect to the historical average. Over the past ten years (40 quarters), ALNY's PE Ratio was at its highest in in the September 2023 quarter at 37.52. The PE Ratio was at its lowest in in the December 2014 quarter at -87.25.

Quarterly (TTM)
Annual

Average

-22.32

Median

-21.71

Minimum

-54.31

Maximum

-7.81

Alnylam Pharmaceuticals, Inc. (ALNY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 199.93%

Maximum Annual PE Ratio = -7.81

Minimum Annual Increase = -71.33%

Minimum Annual PE Ratio = -54.31

Quarterly (TTM)
Annual
YearPE RatioChange
2023-54.31112.42%
2022-25.578.55%
2021-23.5535.27%
2020-17.4122.61%
2019-14.2047.45%
2018-9.63-58.91%
2017-23.44199.93%
2016-7.81-71.33%
2015-27.2636.35%
2014-19.99-54.93%

Alnylam Pharmaceuticals, Inc. (ALNY) Average PE Ratio

How has ALNY PE Ratio performed in the past?

The current PE Ratio of Alnylam Pharmaceuticals, Inc. (ALNY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-34.48

5-year avg

-27.01

10-year avg

-22.32

Alnylam Pharmaceuticals, Inc. (ALNY) PE Ratio vs. Peers

How is ALNY’s PE Ratio compared to its peers?

Alnylam Pharmaceuticals, Inc.’s PE Ratio is less than ProQR Therapeutics N.V. (-5.27), less than Wave Life Sciences Ltd. (-13.04), less than Blueprint Medicines Corporation (-21.96), less than Apellis Pharmaceuticals, Inc. (-11.97), less than Incyte Corporation (17.26), less than United Therapeutics Corporation (12.21), less than Ultragenyx Pharmaceutical Inc. (-5.54), less than BioMarin Pharmaceutical Inc. (69.42), greater than Seagen Inc. (-57.36), less than Exelixis, Inc. (30.17), less than Halozyme Therapeutics, Inc. (17.45), less than Krystal Biotech, Inc. (80.60), less than Madrigal Pharmaceuticals, Inc. (-10.34), greater than Reata Pharmaceuticals, Inc. (-89.36), less than IVERIC bio, Inc. (-33.43), less than Amylyx Pharmaceuticals, Inc. (-1.65), less than Karuna Therapeutics, Inc. (-29.52), less than Day One Biopharmaceuticals, Inc. (-5.71),

Build a custom stock screener for Alnylam Pharmaceuticals, Inc. (ALNY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alnylam Pharmaceuticals, Inc. (ALNY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Alnylam Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Alnylam Pharmaceuticals, Inc. (ALNY)?

What is the highest PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY)?

What is the 3-year average PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY)?

What is the 5-year average PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY)?

How does the current PE Ratio for Alnylam Pharmaceuticals, Inc. (ALNY) compare to its historical average?